CCM
OTLK icon

Coldstream Capital Management’s Outlook Therapeutics OTLK Stock Holding History

Coldstream Capital Management’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-723
Closed -$883 – 2647
2025
Q1 		$883 Buy
+723
New +$1.27K ﹤0.01% 3217

Other funds holding OTLK

SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Coldstream Capital Management's OTLK Position: Q2 2025 in Review

Coldstream Capital Management sold out of Outlook Therapeutics (OTLK) in Q2 2025, closing a stake of 723 shares — an estimated $883 sold.

Coldstream Capital Management first reported a position in OTLK in Q1 2025 and held it in 1 quarter. The position peaked at $883 in Q1 2025. 66 funds tracked by Wall St. Rank hold OTLK as of Q2 2025.

  • Coldstream Capital Management reported no remaining Outlook Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Coldstream Capital Management sold 723 Outlook Therapeutics shares in Q2 2025, an estimated $883.
  • Coldstream Capital Management first reported a position in Outlook Therapeutics in Q1 2025 and held it in 1 quarter.
  • Coldstream Capital Management's Outlook Therapeutics position peaked at $883 in Q1 2025.
  • 66 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q2 2025.

Based on Coldstream Capital Management's 13F filing for Q2 2025, filed 12 Aug 2025.